Dr. Abbey Publishes Case Report on New Approach to Treating Chronic Postoperative Cystoid Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently collaborated with colleagues from the Department of Ophthalmology at University of Texas Southwestern Medical Center in Dallas, to publish a case report in Retinal Cases &
read more
Holiday Office Closure
Happy Holidays from Texas Retina! Our offices will be closed Thursday, December 25, 2025, and Friday, December 26, 2025. We wish you and your family health and happiness this holiday season!
read more
What to Expect at Your Retina Exam
Retina exams are typically more involved than a routine eye exam. At Texas Retina, we make every effort to evaluate, test, diagnose and treat you all on the same day. As a
read more
Keep an Eye on Safety When Choosing Holiday Gifts
Air, BB, pellet and paintball guns may be on children’s holiday wish lists, but are they safe? Eye Injuries from Projectile Toys on the Rise Eye injuries from these types of guns
read more
Dr. Abbey Discusses New Treatment for Macular Telangiectasia Type 2
At AAO 2025, the American Academy of Ophthalmology’s annual meeting, Texas Retina’s Dr. Ashkan Abbey moderated a case-based roundtable discussion about the evolving landscape of macular telangiectasia (MacTel) type 2 care, including
read more
Happy Thanksgiving!
All Texas Retina Associates offices will be closed Thursday, November 27, and Friday, November 28, for the Thanksgiving holiday. During this time of reflection and gratitude, we want you to know how
read more
Control Your Diabetes to Protect Your Vision
November is National Diabetes Month and Diabetic Eye Disease Awareness Month. Diabetes is a disease that occurs when your blood sugar, also known as blood glucose, is too high. It damages blood
read more
Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more

